Tribulosin

Tribulosin at a Glance

Tribulosin is a spirostanol steroidal saponin — a saturated 5α-sapogenin core carrying a branched chain of five sugars, giving a molecule of 1,151 Da that is far too large and too polar to behave like a hormone or cross a membrane unaided. It was isolated from Tribulus terrestris in 1981 ^{7Reference 7Mahato SB et al. · 1981Steroidal glycosides of Tribulus terrestris LinnView study →}, and outside that genus it has essentially never been reported.

Its literature is genuinely tiny. A PubMed search for tribulosin returns nine records in total, of which three are analytical chemistry, one is a computational docking exercise, and only three test the isolated molecule for any biological effect. This page is short because the evidence is short, not because the summary is.

The one finding worth the page is cardioprotection: pretreatment with tribulosin reduced infarct size and apoptosis in isolated rat hearts subjected to ischaemia and reperfusion, an effect the authors attributed to protein kinase C-epsilon ^{1Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →}, with a follow-up in cultured neonatal cardiomyocytes placing PKCε upstream of ERK1/2 ^{2Reference 2Zhang S et al. · 2011In vitroTribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes — in vitroView study →}. Both papers come from the same three-author group at Jilin University, both use preparations in which the molecule is delivered directly to the tissue, and neither has been independently replicated in the fifteen years since. Everything below is written to keep that distinction visible.

Tribulosin Is a Spirostanol — and Its Aglycone Is Not Diosgenin

Two structural facts do most of the interpretive work here.

First, it is a spirostanol, not a furostanol. Tribulus’s famous saponins — protodioscin, prototribestin, protogracillin — are furostanols: open F-ring glycosides carrying an extra glucose at C-26. That C-26 glucose is what a plant enzyme removes. Furostanol glycoside 26-O-β-glucosidase (F26G), purified from Costus speciosus and characterised on protogracillin itself, cleaves it during postharvest treatment and storage, after which the F ring spontaneously closes to the spirostanol form ^{15Reference 15Inoue K · 1996In vitroPurification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomes — in vitroView study →}. So the furostanol/spirostanol pair is not two interchangeable names for the same thing — it is a before-and-after of drying and processing, and a Tribulus preparation’s ratio of the two is largely a record of how it was handled. Chinese stir-frying of Fructus Tribuli pushes this further still: spirostanol saponins fall as they are deglycosylated to free aglycones, while furostanols dehydroxylate and then lose sugars in turn ^{8Reference 8Zhang C et al. · 2020Analysis of variations in the contents of steroidal saponins in Fructus Tribuli during stir-frying treatmentView study →}.

Second, tribulosin’s aglycone is a saturated sapogenin, not diosgenin. The registered structure is the (25S)-5α-spirostan-3β-yl glycoside — that is, neotigogenin, the 25S epimer of tigogenin. Some papers write the aglycone as “tigogenin” ^{2Reference 2Zhang S et al. · 2011In vitroTribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes — in vitroView study →} and one analytical study catalogues a separate 25R-tribulosin ^{8Reference 8Zhang C et al. · 2020Analysis of variations in the contents of steroidal saponins in Fructus Tribuli during stir-frying treatmentView study →}, so the C-25 configuration is inconsistently reported; what is not in doubt is the 5α, fully saturated A/B ring junction. Diosgenin has a Δ5 double bond. Neotigogenin does not.

That matters because of the single most repeated claim in this whole supplement category: that steroidal saponins “convert to progesterone” or “boost DHEA” in the body. They do not. The Marker degradation — the industrial route from diosgenin to progesterone and cortisone — is a multi-step chemical process run in a factory with reagents and heat; the human body has no enzyme that performs it, and no human enzymatic pathway converts a plant sapogenin into a human steroid hormone. For tribulosin the claim is even further from home than usual: its aglycone is not diosgenin at all, so it is not even the compound the factory process starts from. If a Tribulus product changes anything hormonal, tribulosin’s structure gives no reason to think this molecule is why.

The Cardioprotection Evidence, Stated at Its Real Strength

This is the finding the molecule is known for, and it is worth reading in detail rather than in summary.

What was actually done. Zhang, Li and Yang mounted rat hearts on a Langendorff apparatus, subjected them to 30 minutes of ischaemia and 120 minutes of reperfusion, and compared seven groups: control, injury alone, the crude gross saponin fraction of Tribulus terrestris (GSTT) at 100 mg/L, isolated tribulosin at 100, 10 and 1 nmol/L, and the PKC inhibitor chelerythrine at 1 µmol/L ^{1Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →}. Infarct size in the injury group was 40.2% of the total area; GSTT brought it to 24.3%, and tribulosin to 20.2%, 23.2% and 30.3% at the three descending concentrations. Tribulosin also lowered malondialdehyde, AST, creatine kinase and LDH, raised superoxide dismutase, and reduced TUNEL-positive apoptosis concentration-dependently ^{1Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →}.

What the PKC-epsilon evidence consists of. This needs saying plainly, because the claim is routinely repeated as “tribulosin acts via PKCε translocation.” There is no translocation experiment. The evidence is (a) Western blots of total PKCε protein in myocardial tissue, higher after tribulosin preconditioning, alongside higher Bcl-2 and lower Bax and caspase-3; and (b) the reverse pattern in the chelerythrine group ^{1Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →}. Chelerythrine is a broad-spectrum PKC inhibitor with no selectivity for the epsilon isoform. No cytosol/membrane fractionation was performed, no isoform-selective peptide inhibitor such as εV1-2 was used, and no genetic manipulation was involved. The follow-up in neonatal rat ventricular myocytes exposed to hypoxia/reoxygenation adds an epistasis argument — a PKCε inhibitor plus tribulosin reduced ERK1/2, while the MEK inhibitor PD98059 left PKCε unchanged, placing PKCε upstream ^{2Reference 2Zhang S et al. · 2011In vitroTribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes — in vitroView study →} — but it too measures expression, in cell culture. “Consistent with a PKCε-dependent mechanism” is the honest phrasing; “via PKCε translocation” is not.

The three things that limit it most.

• Route. A Langendorff heart is perfused directly. The compound never meets a stomach, a gut wall, a microbiome or a liver. For a 1,151 Da pentaglycoside, that is the entire pharmacokinetic problem skipped in one step.
• Potency. 100 nmol/L is about 0.12 µg/mL. At that concentration isolated tribulosin slightly outperformed the crude saponin fraction dosed at 100 µg/mL — a roughly thousandfold potency difference in favour of a single constituent over the mixture containing it. That is either a remarkable molecule or a result that needs an independent laboratory. It has not had one.
• Replication. Both papers share the same three authors and institution. Fifteen years on, no other group has published on tribulosin and the heart, in any species, by any route. There is no in-vivo whole-animal study, no large animal, and no human.

What the herb’s cardiovascular evidence does not transfer. Tribulus has a real cardiovascular tradition and, unusually, real human data behind it — but the human data are whole extract. Xinnaoshutong, a Chinese preparation made from the ripe fruit of Tribulus terrestris ^{13Reference 13Li J et al. · 2017Simultaneous determination of 5 flavonoids and 7 saponins for quality control of the traditional Chinese medicine preparation Xinnaoshutong capsule (derived from the ripe fruit of Tribulus terrestris) using HPLC-VWD-ELSDView study →}, is one of eleven single-herb oral TCM products assessed in a 2025 network meta-analysis of 72 randomised trials in 7,360 patients with unstable angina, where it ranked among the better performers for reducing angina duration while showing no significant reduction in angina frequency ^{12Reference 12Li X et al. · 2025Meta-analysisEfficacy and safety of 11 oral preparations of single-source traditional Chinese medicines in the treatment of unstable angina pectoris: a systematic review and network meta-analysisView study →}. An older Chinese report treated 406 angina patients with Tribulus saponin against an active comparator and claimed an 82.3% response rate ^{11Reference 11Wang B et al. · 1990Clinical trialWang B, Ma L, Liu T (1990). [406 cases of angina pectoris in coronary heart disease treated with saponin of Tribulus terrestris] — clinical trial, whole-extract, non-placebo active comparator. Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/2364467/View study →} — a 1990 non-placebo trial reporting a composite “total effective rate,” which is a low evidentiary bar. Whole-extract cardioprotection in rats is likewise documented through a MAPK-mediated anti-apoptotic pathway ^{16Reference 16Reshma PL et al. · 2019AnimalPretreatment of Tribulus terrestris L. causes anti-ischemic cardioprotection through MAPK mediated anti-apoptotic pathway in rat — animal model, whole extractView study →}.

None of this is tribulosin. Xinnaoshutong is a multi-saponin, multi-flavonoid fruit extract standardised on twelve markers ^{13Reference 13Li J et al. · 2017Simultaneous determination of 5 flavonoids and 7 saponins for quality control of the traditional Chinese medicine preparation Xinnaoshutong capsule (derived from the ripe fruit of Tribulus terrestris) using HPLC-VWD-ELSDView study →}, made from the kind of East-Asian material in which tribulosin is one of many constituents. A human result on the extract is not a human result on the molecule, and no clinical trial has ever administered isolated tribulosin to anyone.

Tribulosin as a Chemotype Marker

The most reliably useful thing known about tribulosin has nothing to do with pharmacology: it distinguishes chemotypes of the plant.

Dinchev and colleagues profiled Tribulus terrestris from nine countries by LC-ESI/MS/MS and found two clearly separated chemical populations ^{5Reference 5Dinchev D et al. · 2008Distribution of steroidal saponins in Tribulus terrestris from different geographical regionsView study →}. Material from Bulgaria, Turkey, Greece, Serbia, Macedonia, Georgia and Iran shares one profile, dominated by the furostanols protodioscin and prototribestin — this is the Tribestan-type material that carries essentially the whole aphrodisiac and erectile-function literature. Material from Vietnam and India is a different plant chemically: it lacks prototribestin and tribestin entirely, and tribulosin is present in high amounts ^{5Reference 5Dinchev D et al. · 2008Distribution of steroidal saponins in Tribulus terrestris from different geographical regionsView study →}.

This inverts the usual standardisation story. Everywhere else in this batch, “Bulgarian material is the good material” is the correct simplification, because Bulgarian material is protodioscin-rich. For tribulosin specifically the opposite holds — the South and Southeast Asian chemotype is the tribulosin-rich one, and the European material studied for sexual function is comparatively poor in it. Consistent with that, the only quantitative figures for tribulosin come from Indian material: HPTLC of fourteen wild populations from Rajasthan and adjoining regions found 0.028–0.158% of dry weight, against 0.002–0.028% for diosgenin in the same samples, with the variation tracking geography and correlating with antioxidant capacity ^{6Reference 6Limboo A et al. · 2026Pharmacopoeial standardisation and bioactive metabolite-based identification of elite sources of Tribulus terrestris L. from Rajasthan and adjoining regions, IndiaView study →}.

The practical consequence is uncomfortable for both sides. A European-chemotype Tribulus extract standardised to furostanol saponins may contain very little tribulosin. An Indian or Vietnamese Tribulus powder may contain a good deal of it — but carries none of the clinical literature. Neither is a route to the molecule.

What It's Used For

Three biological studies exist on the isolated compound. All are ex-vivo, in-vitro or in-silico; none is a living-animal oral study, and none is human.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every score here is capped by the same two facts: a total corpus of nine papers, and no study in which an intact animal was given tribulosin by mouth.

01Cardioprotection (ischaemia/reperfusion)Shaky30%Isolated molecule, Langendorff rat heart + neonatal cardiomyocytes; one laboratory, two papers, no replication ^{1,2Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →Reference 2Zhang S et al. · 2011In vitroTribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes — in vitroView study →}

02AnthelminticShaky20%Bioassay-guided isolation, ED50 76.25 µg/mL against C. elegans in vitro; single study, plausibly a membrane effect ^{3,4Reference 3Deepak M et al. · 2002In vitroTribulosin and β-sitosterol-D-glucoside, the anthelmintic principles of Tribulus terrestris — in vitroView study →Reference 4Efimova SS · 2021In vitroIs the membrane lipid matrix a key target for action of pharmacologically active plant saponins? — in vitro, model lipid bilayersView study →}

03AntioxidantShaky16%Secondary endpoints (↓MDA, ↑SOD) inside the same I/R experiment; plus an extract-level correlation in Indian populations ^{1,6Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →Reference 6Limboo A et al. · 2026Pharmacopoeial standardisation and bioactive metabolite-based identification of elite sources of Tribulus terrestris L. from Rajasthan and adjoining regions, IndiaView study →}

Mechanisms

Only the bottom two rows describe experiments performed on the molecule outside a heart preparation, and one of them is a computer simulation. The mechanism table is thin because the literature is.

Pharmacokinetics

There is no pharmacokinetic study of tribulosin. No absorption figure, no oral bioavailability, no half-life, no metabolite identification, no tissue distribution — nothing.

What can be said comes from structure and from neighbours. Tribulosin is a pentaglycoside of 1,151 Da carrying rhamnose, galactose, glucose and two xyloses; molecules of that size and polarity are poorly absorbed intact, and the general expectation for steroidal saponins is that gut microbiota strip the sugars and the deglycosylated sapogenin is what reaches tissue. For tribulosin that sapogenin would be neotigogenin — a saturated 5α-sapogenin, not diosgenin, and a compound with no pharmacology of its own on record here. The same deglycosylation is demonstrable chemically: stir-frying Fructus Tribuli reduces spirostanol saponin content precisely by converting them to free aglycones ^{8Reference 8Zhang C et al. · 2020Analysis of variations in the contents of steroidal saponins in Fructus Tribuli during stir-frying treatmentView study →}.

The one relevant measurement is indirect. A validated UHPLC-MS/MS study followed six Tribulus steroidal saponins in rat plasma after oral crude and stir-fried fruit extract, and all six were quantifiable, with stir-frying significantly changing Cmax and AUC for several of them ^{14Reference 14Song X et al. · 2021AnimalPharmacokinetic comparisons of six steroid saponins in rat plasma following oral administration of crude and stir-fried Fructus Tribuli extracts by UHPLC-MS/MS — animal modelView study →}. So intact Tribulus saponins are not simply undetectable after oral dosing. Tribulosin was not one of the six analytes, however, and no figure exists for it.

This is the page’s central unresolved problem. The cardioprotection was produced by 1–100 nmol/L of the intact glycoside delivered straight into a coronary circulation. Nobody has shown that intact tribulosin reaches a beating heart in a living animal after an oral dose, and nobody has shown that it reaches nanomolar plasma concentrations. Until someone does, the finding describes what the molecule can do to heart tissue, not what swallowing it does to a heart.

Clinical Trials

None. No trial, completed, ongoing or registered, has administered isolated tribulosin to a human being. The clinical literature attached to this plant uses standardised whole extracts — the furostanol-standardised Bulgarian Tribestan type for sexual function, and the Tribulus fruit preparation Xinnaoshutong for angina ^{12,13Reference 12Li X et al. · 2025Meta-analysisEfficacy and safety of 11 oral preparations of single-source traditional Chinese medicines in the treatment of unstable angina pectoris: a systematic review and network meta-analysisView study →Reference 13Li J et al. · 2017Simultaneous determination of 5 flavonoids and 7 saponins for quality control of the traditional Chinese medicine preparation Xinnaoshutong capsule (derived from the ripe fruit of Tribulus terrestris) using HPLC-VWD-ELSDView study →} — neither of which is a tribulosin trial.

Last checked: August 2026.

Isolate vs. Plant Studies

Tribulosin sits at an unusual point on this axis: almost all of its own literature is isolate work, and almost none of it is in a living organism.

The isolate side is real. The cardioprotection studies used purified tribulosin and, in the first, ran the crude gross saponin fraction as a side-by-side comparator ^{1Reference 1Zhang S et al. · 2010AnimalTribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal modelView study →}. The anthelmintic result came from bioassay-guided fractionation, which is the honest way to attribute an extract’s activity to a molecule ^{3Reference 3Deepak M et al. · 2002In vitroTribulosin and β-sitosterol-D-glucoside, the anthelmintic principles of Tribulus terrestris — in vitroView study →}. The membrane biophysics used the pure compound on defined synthetic bilayers ^{4Reference 4Efimova SS · 2021In vitroIs the membrane lipid matrix a key target for action of pharmacologically active plant saponins? — in vitro, model lipid bilayersView study →}. On paper, that is a better isolate record than most molecules in this batch.

The plant side is where the transferability fails, and it fails in the direction people rarely expect. The human evidence for Tribulus in cardiovascular disease is whole-extract, and mostly Chinese-language and older ^{11,12Reference 11Wang B et al. · 1990Clinical trialWang B, Ma L, Liu T (1990). [406 cases of angina pectoris in coronary heart disease treated with saponin of Tribulus terrestris] — clinical trial, whole-extract, non-placebo active comparator. Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/2364467/View study →Reference 12Li X et al. · 2025Meta-analysisEfficacy and safety of 11 oral preparations of single-source traditional Chinese medicines in the treatment of unstable angina pectoris: a systematic review and network meta-analysisView study →}. Worse, the extract behind that human evidence is made from East Asian Tribulus fruit, while the chemotype work shows tribulosin is the marker of Indian and Vietnamese material ^{5Reference 5Dinchev D et al. · 2008Distribution of steroidal saponins in Tribulus terrestris from different geographical regionsView study →}. So the human data, the animal isolate data and the abundance data do not even come from the same plant populations. There is no chain of evidence running from “tribulosin does this in a perfused heart” to “Tribulus helps angina in people,” and the honest position is that the two literatures currently sit beside each other without touching.

Prevalence in Nature

Tribulosin is, so far as the published record goes, a Tribulus compound. It has been reported from Tribulus terrestris (Zygophyllaceae) throughout the plant’s range, and from the roots of the related Tribulus cistoides, where it was isolated alongside a pregnane-type glycoside and eight new cholestane glycosides ^{9Reference 9Achenbach H et al. · 1996Cholestane- and pregnane-type glycosides from the roots of Tribulus cistoidesView study →}. No credible report places it in another genus.

Within T. terrestris, its distribution is chemotypic rather than uniform. The European–West Asian chemotype (Bulgaria, Turkey, Greece, Serbia, Macedonia, Georgia, Iran) is dominated by furostanols and is comparatively poor in tribulosin; the Vietnamese and Indian chemotype lacks prototribestin and tribestin altogether and carries tribulosin in high amounts ^{5Reference 5Dinchev D et al. · 2008Distribution of steroidal saponins in Tribulus terrestris from different geographical regionsView study →}. Only one quantitative dataset exists — fourteen wild Indian populations at 0.028–0.158% of dry weight, measured by validated HPTLC, with diosgenin an order of magnitude lower in the same samples ^{6Reference 6Limboo A et al. · 2026Pharmacopoeial standardisation and bioactive metabolite-based identification of elite sources of Tribulus terrestris L. from Rajasthan and adjoining regions, IndiaView study →}.

Source	Part	Tribulosin	Note
Tribulus (T. terrestris), Indian wild populations	plant material	0.028–0.158% dry wt	The only published quantification of this molecule 6Reference 6Limboo A et al. · 2026Pharmacopoeial standardisation and bioactive metabolite-based identification of elite sources of Tribulus terrestris L. from Rajasthan and adjoining regions, IndiaView study →
T. terrestris, Vietnamese and Indian samples	aerial parts, fruit	”high amounts”, not quantified	The tribulosin-rich chemotype; lacks prototribestin and tribestin 5Reference 5Dinchev D et al. · 2008Distribution of steroidal saponins in Tribulus terrestris from different geographical regionsView study →
T. terrestris, Bulgarian/Turkish/Greek/Balkan/Georgian/Iranian	aerial parts, fruit	present, comparatively low	Protodioscin- and prototribestin-dominated material 5Reference 5Dinchev D et al. · 2008Distribution of steroidal saponins in Tribulus terrestris from different geographical regionsView study →
Tribulus cistoides	root	not quantified	Isolated with cholestane and pregnane glycosides 9Reference 9Achenbach H et al. · 1996Cholestane- and pregnane-type glycosides from the roots of Tribulus cistoidesView study →

Two processing variables move these numbers. Drying and storage raise spirostanol content, because the plant’s own F26G glucosidase converts furostanols into their spirostanol counterparts postharvest ^{15Reference 15Inoue K · 1996In vitroPurification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomes — in vitroView study →}. Stir-frying lowers it, by deglycosylating spirostanol saponins to free aglycones ^{8Reference 8Zhang C et al. · 2020Analysis of variations in the contents of steroidal saponins in Fructus Tribuli during stir-frying treatmentView study →}. A tribulosin figure without a stated processing history is therefore only loosely interpretable.

Discovery & Synthesis

Tribulosin was first isolated in 1981 by Shashi B. Mahato, Niranjan P. Sahu and Amar N. Ganguly at the Indian Institute of Experimental Medicine in Calcutta, working with Kazumoto Miyahara and Toshio Kawasaki, and reported in Journal of the Chemical Society, Perkin Transactions 1 as one of two new steroidal glycosides from the aerial parts of Tribulus terrestris ^{7Reference 7Mahato SB et al. · 1981Steroidal glycosides of Tribulus terrestris LinnView study →}. The name is straightforwardly generic — Tribulus plus the saponin suffix — and should not be confused with tribuloside, an unrelated flavonoid (a kaempferol coumaroyl glucoside) that appears in the same plant and in a much larger literature.

The structure assigned was the neotigogenin 3-O-pentaglycoside: a (25S)-5α-spirostan-3β-ol core bearing β-D-galactose at C-3, substituted with α-L-rhamnose at the galactose 2-position and β-D-glucose at the 4-position, the glucose in turn carrying β-D-xylose units at its 2- and 3-positions. Formula C55H90O25, MW 1,151.3, CAS 79974-46-2. Later papers are inconsistent about C-25 — one gives the aglycone as tigogenin ^{2Reference 2Zhang S et al. · 2011In vitroTribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes — in vitroView study →} and an analytical study catalogues 25R-tribulosin as a distinct entity ^{8Reference 8Zhang C et al. · 2020Analysis of variations in the contents of steroidal saponins in Fructus Tribuli during stir-frying treatmentView study →} — so the epimeric assignment should be treated as unsettled in the secondary literature even though the registered structure is 25S.

No total synthesis has been reported, and there is no commercial production. Material for research is obtained by extraction and chromatographic purification from T. terrestris, and the compound is sold only as an analytical standard in milligram quantities. Nothing about the molecule’s economics resembles the industrial sapogenin trade, which works on cheap unglycosylated aglycones such as diosgenin and hecogenin rather than on intact pentaglycosides.

Patents: not yet researched.

Toxicity & Safety

Tribulosin carries an unknown flag, and that is a statement of fact rather than a hedge: no toxicology study of any kind has been performed on this molecule. No acute or repeat-dose study, no genotoxicity battery, no reproductive or developmental work, no CYP or transporter interaction data, no haemolysis figure. Safety cannot be inferred from the absence of reports when nobody has looked.

Three specific reasons argue against defaulting to “probably fine.”

It is a demonstrated membrane-active agent. Not by class analogy — by direct measurement. On phosphatidylcholine bilayers tribulosin substantially reduced boundary potential and altered the membrane dipole potential enough to change gramicidin A channel conductance and lifetime, behaving like digitonin and dioscin in the same experiments ^{4Reference 4Efimova SS · 2021In vitroIs the membrane lipid matrix a key target for action of pharmacologically active plant saponins? — in vitro, model lipid bilayersView study →}. Membrane perturbation is the standard mechanism behind saponin haemolysis and behind non-selective cytotoxicity, and it means any future “kills cancer cells at X µM” report on tribulosin should be read with a selectivity index against normal cells demanded up front — none has ever been published for this compound.

Its closest structural sibling in the same plant is a toxin. Terrestrosin D, also a Tribulus spirostanol saponin, has been identified as a likely driver of the herb’s hepatorenal toxicity, in vitro and in a 28-day rat study ^{17Reference 17Sun XC et al. · 2022In vitroTerrestrosin D, a spirostanol saponin from Tribulus terrestris L. with potential hepatorenal toxicity — in vitro and 28-day rat study, animal modelView study →}. Structural proximity is not evidence of shared toxicity, but it removes any presumption that spirostanol saponins from this plant are benign by default.

The parent herb has real documented harms. Tribulus supplements have been associated with drug-induced liver injury, acute kidney injury and rhabdomyolysis in case reports, and in ruminants the plant causes hepatogenous photosensitisation. Two Turkish case series also describe acute coronary syndrome and stent thrombosis in patients taking a Tribulus-containing combination product alongside dual antiplatelet therapy ^{18,19Reference 18Vatankulu MA et al. · 2012Case reportVatankulu MA, Tasal A, Erdoğan E, Göktekin Ö (2012). [Three case reports of the use of herbal combinations resulting in stent thrombosis: herbal combinations, friend or foe?] — case series. Türk Kardiyoloji Derneği Arşivi. https://pubmed.ncbi.nlm.nih.gov/22864325/View study →Reference 19Atar Aİ et al. · 2012Case reportAtar Aİ, Er O, Güven A, Eryonucu B (2012). [Two cases of acute coronary syndrome after intake of Clavis Panax (Panax ginseng, Tribulus terrestris, oat)] — case report. Türk Kardiyoloji Derneği Arşivi. https://pubmed.ncbi.nlm.nih.gov/22864326/View study →} — a pointed counterweight to the cardioprotection headline, though the product contained ginseng and oat as well and no molecule was implicated. The full picture belongs on the tribulus monograph, where intake is actually decided.

Reproductive and developmental data for isolated tribulosin do not exist; nothing on the plant’s reproductive pharmacology has been attributed to this molecule.

Safety at a Glance

❔ Toxicity unknown

• No toxicology whatsoever. Zero studies on the isolated molecule — no acute, repeat-dose, genotoxicity, reproductive or interaction data. Silence here is absence of investigation, not evidence of safety.
• Directly demonstrated membrane activity. Tribulosin alters lipid bilayer boundary and dipole potentials and modifies ion channel behaviour ^{4Reference 4Efimova SS · 2021In vitroIs the membrane lipid matrix a key target for action of pharmacologically active plant saponins? — in vitro, model lipid bilayersView study →} — the mechanism underlying saponin haemolysis and non-selective cytotoxicity.
• A sibling spirostanol from the same plant is hepatorenally toxic. Terrestrosin D is the identified toxicology lead in Tribulus ^{17Reference 17Sun XC et al. · 2022In vitroTerrestrosin D, a spirostanol saponin from Tribulus terrestris L. with potential hepatorenal toxicity — in vitro and 28-day rat study, animal modelView study →}; do not assume this structural class is benign.
• Do not read “cardioprotective” as cardiac-safe. The effect exists in perfused rat hearts at nanomolar perfusate concentrations; case reports of acute coronary events on Tribulus-containing products in patients on antiplatelet therapy point the other way ^{18,19Reference 18Vatankulu MA et al. · 2012Case reportVatankulu MA, Tasal A, Erdoğan E, Göktekin Ö (2012). [Three case reports of the use of herbal combinations resulting in stent thrombosis: herbal combinations, friend or foe?] — case series. Türk Kardiyoloji Derneği Arşivi. https://pubmed.ncbi.nlm.nih.gov/22864325/View study →Reference 19Atar Aİ et al. · 2012Case reportAtar Aİ, Er O, Güven A, Eryonucu B (2012). [Two cases of acute coronary syndrome after intake of Clavis Panax (Panax ginseng, Tribulus terrestris, oat)] — case report. Türk Kardiyoloji Derneği Arşivi. https://pubmed.ncbi.nlm.nih.gov/22864326/View study →}.
• Long dietary and medicinal exposure at trace levels. Tribulus fruit is a food-adjacent Ayurvedic and Chinese medicinal with centuries of use, and tribulosin makes up under 0.2% of dry plant material ^{6Reference 6Limboo A et al. · 2026Pharmacopoeial standardisation and bioactive metabolite-based identification of elite sources of Tribulus terrestris L. from Rajasthan and adjoining regions, IndiaView study →}.

Dosage

There is no human dose of tribulosin, no supplement supplies the isolated molecule, and no Tribulus product is standardised to it. The figures below are experimental settings, listed for orientation only.

The two isolate concentrations differ by roughly 660-fold, which is itself informative: the cardiac effect is claimed at a concentration where a saponin’s surfactant chemistry is irrelevant, while the anthelmintic effect sits squarely in the range where it dominates. Neither has an oral-exposure equivalent, because no absorption figure exists. These are doses studied in research and are not a personal recommendation.

References

1. Zhang S, Li H, Yang SJ (2010). Tribulosin protects rat hearts from ischemia/reperfusion injury — isolated Langendorff-perfused rat heart, animal model. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/20453871/
2. Zhang S, Li H, Yang SJ (2011). Tribulosin suppresses apoptosis via PKC epsilon and ERK1/2 signaling pathway during hypoxia/reoxygenation in neonatal rat ventricular cardiac myocytes — in vitro. Journal of Asian Natural Products Research. https://pubmed.ncbi.nlm.nih.gov/22115037/
3. Deepak M, Dipankar G, Prashanth D, Asha MK, Amit A, Venkataraman BV (2002). Tribulosin and β-sitosterol-D-glucoside, the anthelmintic principles of Tribulus terrestris — in vitro. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/12587699/
4. Efimova SS, Ostroumova OS (2021). Is the membrane lipid matrix a key target for action of pharmacologically active plant saponins? — in vitro, model lipid bilayers. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/33804648/
5. Dinchev D, Janda B, Evstatieva L, Oleszek W, Aslani MR, Kostova I (2008). Distribution of steroidal saponins in Tribulus terrestris from different geographical regions. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/17719068/
6. Limboo A, Pradhan D, Singh AL, Srivastava S (2026). Pharmacopoeial standardisation and bioactive metabolite-based identification of elite sources of Tribulus terrestris L. from Rajasthan and adjoining regions, India. Natural Product Research. https://doi.org/10.1080/14786419.2026.2653209
7. Mahato SB, Sahu NP, Ganguly AN, Miyahara K, Kawasaki T (1981). Steroidal glycosides of Tribulus terrestris Linn. Journal of the Chemical Society, Perkin Transactions 1. https://doi.org/10.1039/p19810002405
8. Zhang C, Wang S, Guo F, Ma T, Zhang L, Sun L, Wang Y, Zhang X (2020). Analysis of variations in the contents of steroidal saponins in Fructus Tribuli during stir-frying treatment. Biomedical Chromatography. https://pubmed.ncbi.nlm.nih.gov/31944362/
9. Achenbach H, Hübner H, Reiter M (1996). Cholestane- and pregnane-type glycosides from the roots of Tribulus cistoides. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/8835464/
10. Kumar B, Misra A, Singh SP, Dhar YV, Rawat P, Chattopadhyay D, Barik SK, Srivastava S (2021). In-silico efficacy of potential phytomolecules from Ayurvedic herbs as an adjuvant therapy in management of COVID-19 — computational docking, in vitro validation absent. Journal of Food and Drug Analysis. https://pubmed.ncbi.nlm.nih.gov/35649148/
11. Wang B, Ma L, Liu T (1990). [406 cases of angina pectoris in coronary heart disease treated with saponin of Tribulus terrestris] — clinical trial, whole-extract, non-placebo active comparator. Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/2364467/
12. Li X, Li X, Zhu X, Xin X, Sheng R, Wang T, Kan J, Huang Y (2025). Efficacy and safety of 11 oral preparations of single-source traditional Chinese medicines in the treatment of unstable angina pectoris: a systematic review and network meta-analysis. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/40630122/
13. Li J, Bai Y, Zhang P, He J, Cao J, An M, Hu LM, Gao XM, Chang YX (2017). Simultaneous determination of 5 flavonoids and 7 saponins for quality control of the traditional Chinese medicine preparation Xinnaoshutong capsule (derived from the ripe fruit of Tribulus terrestris) using HPLC-VWD-ELSD. Journal of Analytical Methods in Chemistry. https://pubmed.ncbi.nlm.nih.gov/28191359/
14. Song X, Yuan Y, Wang S, Sun X, Zhang C, Gao P, Shi L (2021). Pharmacokinetic comparisons of six steroid saponins in rat plasma following oral administration of crude and stir-fried Fructus Tribuli extracts by UHPLC-MS/MS — animal model. Biomedical Chromatography. https://pubmed.ncbi.nlm.nih.gov/33939847/
15. Inoue K, Ebizuka Y (1996). Purification and characterization of furostanol glycoside 26-O-β-glucosidase from Costus speciosus rhizomes — in vitro. FEBS Letters. https://pubmed.ncbi.nlm.nih.gov/8549824/
16. Reshma PL, Binu P, Anupama N, Vineetha RC, et al. (2019). Pretreatment of Tribulus terrestris L. causes anti-ischemic cardioprotection through MAPK mediated anti-apoptotic pathway in rat — animal model, whole extract. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/30841448/
17. Sun XC, Song X, Guo F, Yuan Y, Wang S, Wang XY, Han B, Zhang C, Liu JT (2022). Terrestrosin D, a spirostanol saponin from Tribulus terrestris L. with potential hepatorenal toxicity — in vitro and 28-day rat study, animal model. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/34626781/
18. Vatankulu MA, Tasal A, Erdoğan E, Göktekin Ö (2012). [Three case reports of the use of herbal combinations resulting in stent thrombosis: herbal combinations, friend or foe?] — case series. Türk Kardiyoloji Derneği Arşivi. https://pubmed.ncbi.nlm.nih.gov/22864325/
19. Atar Aİ, Er O, Güven A, Eryonucu B (2012). [Two cases of acute coronary syndrome after intake of Clavis Panax (Panax ginseng, Tribulus terrestris, oat)] — case report. Türk Kardiyoloji Derneği Arşivi. https://pubmed.ncbi.nlm.nih.gov/22864326/

View all 19 references▾